We have been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 100 distinguished scientific, medical, investment, and other professionals manages over $18 billion across public and private company investments worldwide.
Life Sciences Focus
The global healthcare industry sits at the intersection of several powerful long-term growth trends led by global demographics and the ineluctable advance of scientific innovation in treating disease.

These trends have caused a steady increase in the level of healthcare spending in the industrialized world, led by the U.S. which now spends over 17% of its GDP on healthcare. We believe the healthcare industry's powerful growth profile coupled with its magnitude and complexity create myriad investment opportunities.

Our Strategies
OrbiMed invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made in one of three strategies: public equity, private equity, and private credit/royalty.

Public Equity
OrbiMed manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. We invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide.
Private Equity
OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, helping to build our portfolio companies into market leaders. We invest globally, including across North America, Asia, and Europe.
Private Credit/Royalty
OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, OrbiMed can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.